<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00278252</url>
  </required_header>
  <id_info>
    <org_study_id>CCLG-CNS-2001-4</org_study_id>
    <secondary_id>CDR0000454543</secondary_id>
    <secondary_id>EU-20576</secondary_id>
    <nct_id>NCT00278252</nct_id>
  </id_info>
  <brief_title>Etoposide in Treating Young Patients With Relapsed Ependymoma</brief_title>
  <official_title>Phase II Study of Intravenous Etoposide in Patients With Relapsed Ependymoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Cancer and Leukaemia Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as etoposide, work in different ways to stop the&#xD;
      growth of tumor cells, either by killing the cells or by stopping them from dividing.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well etoposide works in treating young patients&#xD;
      with ependymoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the response rate in young patients with relapsing and/or refractory&#xD;
           ependymoma treated with a rapid schedule of intravenous etoposide.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the possibility of second surgery or additional radiotherapy in these&#xD;
           patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive etoposide IV over 1 hour on days 1-3, 8-10, and 15-17. Treatment repeats&#xD;
      every 28 days for up to 6 courses in the absence of disease progression or unacceptable&#xD;
      toxicity. Patients whose tumor becomes resectable after courses 3 or 6 undergo surgical&#xD;
      resection.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for approximately 5&#xD;
      years.&#xD;
&#xD;
      PROJECTED ACCRUAL: At least 14 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2001</start_date>
  <primary_completion_date type="Anticipated">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate by MRI after course 3</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Second surgery or additional radiotherapy in responding patients as assessed by MRI scan after course 3 or 6</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed intracranial ependymoma at first, second, or third relapse&#xD;
&#xD;
               -  Anaplastic (malignant) or low-grade ependymoma (cellular, papillary, clear cell,&#xD;
                  or mixed variants)&#xD;
&#xD;
          -  Unequivocal evidence of tumor recurrence or progression by MRI scan after failing&#xD;
             conventional treatment (e.g., primary surgery and adjuvant radiotherapy) for initial&#xD;
             or recurrent disease&#xD;
&#xD;
          -  Unresectable disease OR not amenable to complete surgical resection&#xD;
&#xD;
          -  Measurable enhancing or non-enhancing disease on baseline scan performed within the&#xD;
             past 2 weeks&#xD;
&#xD;
               -  Patients who have undergone prior surgery must have residual measurable disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Lansky performance status 30-100%&#xD;
&#xD;
          -  Life expectancy â‰¥ 8 weeks&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,000/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
          -  Serum total bilirubin normal&#xD;
&#xD;
          -  AST &lt; 2 times upper limit of normal&#xD;
&#xD;
          -  No unrelated medical condition (e.g., renal or liver impairment) that would preclude&#xD;
             chemotherapy treatment&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No radiotherapy within the past 6 weeks&#xD;
&#xD;
          -  No chemotherapy within the past 4 weeks&#xD;
&#xD;
          -  Prior IV etoposide allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda S. Lashford</last_name>
    <affiliation>The Christie NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susan V. Picton, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Leeds Cancer Centre at St. James's University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leeds Cancer Centre at St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan V. Picton, MD</last_name>
      <phone>44-11-32-064-985</phone>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>January 16, 2006</study_first_submitted>
  <study_first_submitted_qc>January 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2006</study_first_posted>
  <last_update_submitted>August 6, 2013</last_update_submitted>
  <last_update_submitted_qc>August 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2013</last_update_posted>
  <keyword>recurrent childhood ependymoma</keyword>
  <keyword>childhood infratentorial ependymoma</keyword>
  <keyword>childhood supratentorial ependymoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ependymoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

